Clinical Hematology International

Volume 2, Issue 1, March 2020, Pages 18 - 26

Clinical Advancement and Challenges of ex vivo Expansion of Human Cord Blood Cells

Authors
Oluwadunni E. Emiloju1, *, Rashmika Potdar2, Vinicius Jorge2, Sorab Gupta2, Gabor Varadi2
1Department Of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA
2Hematology and Oncology Department, Albert Einstein Medical Center, Philadelphia, PA, USA
*Corresponding author. Email: emilojuo@einstein.edu
Corresponding Author
Oluwadunni E. Emiloju
Received 5 September 2019, Accepted 16 November 2019, Available Online 4 December 2019.
DOI
10.2991/chi.d.191121.001How to use a DOI?
Keywords
Umbilical cord blood; UCB; Transplantation; Engraftment; HSPC; Expansion; Homing; Regulatory T cells
Abstract

Apart from peripheral blood stem cell (PBSC), umbilical cord blood (UCB) is now a recognized source of stem cells for transplantation. UCB is an especially important source of stem cells for minority populations, which would otherwise be unable to find appropriately matched adult donors. UCB has fewer mature T lymphocytes compared with peripheral blood, thus making a UCB transplantation (UCBT) with a greater degree of HLA mismatch possible. The limited cell dose per UCB sample is however associated with delayed engraftment and a higher risk of graft failure, especially in adult recipients. This lower cell dose can be optimized by performing double unit UCBT, ex vivo UCB expansion prior to transplant and enhancement of the capabilities of the stem cells to home to the bone marrow. UCB contains naïve and immature T cells, thus posing significant challenges with increased risk of infections, graft versus host diseases (GVHD) and relapse following UCBT. Cell engineering techniques have been developed to circumnavigate the immaturity of the T cells, and include virus-specific cytotoxic T cells (VSTs), T cells transduced with disease-specific chimeric antigen receptor (CAR T cells) and regulatory T cell (Tregs) engineering. In this article, we review the advances in UCB ex vivo expansion and engineering to improve engraftment and reduce complications. As further research continues to find ways to overcome the current challenges, outcomes from UCBT will likely improve.

Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Clinical Hematology International
Volume-Issue
2 - 1
Pages
18 - 26
Publication Date
2019/12/04
ISSN (Online)
2590-0048
DOI
10.2991/chi.d.191121.001How to use a DOI?
Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Oluwadunni E. Emiloju
AU  - Rashmika Potdar
AU  - Vinicius Jorge
AU  - Sorab Gupta
AU  - Gabor Varadi
PY  - 2019
DA  - 2019/12/04
TI  - Clinical Advancement and Challenges of ex vivo Expansion of Human Cord Blood Cells
JO  - Clinical Hematology International
SP  - 18
EP  - 26
VL  - 2
IS  - 1
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.191121.001
DO  - 10.2991/chi.d.191121.001
ID  - Emiloju2019
ER  -